<DOC>
	<DOCNO>NCT00161291</DOCNO>
	<brief_summary>The purpose study determine pathological response maximum 18 week neoadjuvant therapy use combination letrozole Bevacizumab post-menopausal woman pathologically confirm invasive ductal cancer invasive lobular cancer breast whose tumor hormone positive .</brief_summary>
	<brief_title>Open Label Trial Post-Menopausal Women With Newly Diagnosed Operable Breast Cancer</brief_title>
	<detailed_description>This open label , single arm , Phase II study combination Letrozole Bevacizumab patient newly diagnose breast cancer . Patients meet eligibility criterion sign consent form start Letrozole 2.5 mg mouth day Bevacizumab 15 mg per Kg IV every 3 week 18 week ( 24 week still respond week 18 approve PI ) . After neoadjuvant therapy , participant undergo surgical treatment receive adjuvant therapy accord treat physician .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Letrozole</mesh_term>
	<criteria>Pathologically confirm invasive ductal carcinoma invasive lobular carcinoma breast , T2T4 / T4ac / N02 / M0 , positive estrogen and/or progesterone receptor . Patients inflammatory breast cancer include ( Stage IIIb ) . Patients previously treat patient measurable disease patient metastatic disease exclude . Written inform consent prior study specific screening procedure , understand patient right withdraw study time , without prejudice ( see Appendix B consent form ) . Females 60 year age ( postmenopausal ) . Be ambulatory ( outpatient ) ECOG PS &lt; 2 ( Appendix F ) . Patients must measurable disease mammogram and/or breast ultrasound . The target lesion must previously irradiate . No prior chemotherapy . Patients must adequate organ marrow function define follow : absolute neutrophil count &gt; 1,500/mm3 , hemoglobin &gt; 8.0 g/dl , platelet &gt; 75,000/mm3 , total bilirubin &lt; 2 mg/dl , serum creatinine &lt; 2 mg/dl , Transaminases ( AST , ALT ) may 2.0 x institutional upper limit normal . In addition &lt; 1 gr protein 24 hr urine collection urine protein/creatinine ratio &lt; 1.0 . No life threaten parenchymal disease rapidly progress disease warrant cytotoxic chemotherapy . Hypertension must control ( &lt; 150/100 mmHg ) . Ejection Fraction &gt; 50 % . No history thrombosis previous year . Current , recent ( within 4 week first infusion study ) , plan participation experimental drug study sponsorinvestigator Bevacizumab cancer study . Uncontrolled high blood pressure ( 150/100 mmHg ) Unstable angina New York Heart Association ( NYHA ) Grade II great congestive heart failure see Appendix G ) History myocardial infarction within 6 month History stroke within 6 month Clinically significant peripheral vascular disease History bleed disorder Presence central nervous system brain metastasis Major surgical procedure , open biopsy , significant traumatic injury within 28 day prior Day 0 , anticipation need major surgical procedure course study Minor surgical procedure , fine needle aspiration core biopsy within 7 day prior Day 0 Pregnant ( positive pregnancy test ) lactate Urine protein : creatinine ratio 1.0 screening . Patients demonstrate &gt; 1 gr protein 24 hr urine collection within 4 week prior study entry participate trial . History abdominal fistula , gastrointestinal perforation , intraabdominal abscess within 6 month prior Day 0 Serious , nonhealing wound , ulcer , bone fracture Unwilling unable comply protocol duration study . Psychiatric illness/social situation would limit compliance study requirement . History another malignancy within last five year except cure basal cell carcinoma skin carcinoma insitu uterine cervix . Patients metastatic disease .</criteria>
	<gender>Female</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2010</verification_date>
	<keyword>Carcinoma breast</keyword>
	<keyword>Breast cancer</keyword>
</DOC>